Life Sciences Daily Summary: What Happened on October 6, 2026

Survodutide met both Phase 3 endpoints, but gastrointestinal effects led some patients to stop

The 755-person SYNCHRONIZE-2 trial met both co-primary endpoints: weight change and the share of participants who lost at least 5% of their weight.2 At week 76, average weight loss reached 13.1% with survodutide versus 3.1% with placebo under an analysis that assumes participants stayed on treatment.12 When the analysis included outcomes regardless of whether participants stopped treatment, weight loss was 9.8% at the 6.0-mg dose and 8.2% at 3.6 mg, versus 3.9% with placebo.2

The drug also reduced HbA1c, a measure of average blood sugar, by up to 1.21 percentage points from a baseline of 7.4%, compared with 0.03 points on placebo.12 Gastrointestinal events led 18% of survodutide recipients to stop treatment, compared with 1.2% of placebo recipients, usually during dose escalation.2 Boehringer Ingelheim said a rigid dose-escalation schedule may have contributed to the discontinuations. The company said newer trials allow more flexible dose increases.2

Survodutide is an investigational dual glucagon and GLP-1 receptor agonist and is not approved in any market.12 The trial compared it with placebo, not approved incretin medicines, so its performance against those treatments remains unknown.2

Epcoritamab plus R-CHOP lowered progression-or-death risk by 51% in lymphoma

An interim analysis of the Phase 3 EPCORE DLBCL-2 trial found that epcoritamab plus R-CHOP significantly improved progression-free survival compared with R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma.4 The combination reduced the likelihood of disease progression or death by 51%, and its reported safety profile was generally consistent with what was already known about the medicines.34

An independent data monitoring committee recommended unblinding the study after the benefit emerged.4 The companies plan to present the full results at a future medical meeting and discuss next steps with regulators.4 The combination remains investigational in this setting. The trial compared it with R-CHOP alone, not the Polivy-based regimen used in frontline care.34

Roche pays Alector $100 million upfront for a preclinical Parkinson’s candidate

Roche licensed global rights to AL050, a preclinical enzyme replacement therapy designed to address GCase deficiency in Parkinson’s disease.5 Alector is eligible for up to $1.17 billion in development, regulatory and commercial milestones, bringing the deal’s potential value to $1.27 billion.5

Genentech will lead development, regulatory work, manufacturing and commercialization across indications.5 Alector retains ownership of its ABC delivery platform, which the company says is designed to carry therapies across the blood-brain barrier.5

CSL commits $355 million upfront to Alentis’s kidney and liver drug

CSL signed an exclusive collaboration with Alentis Therapeutics to develop and commercialize lixudebart for kidney and liver diseases.6 Alentis will receive $355 million upfront and may collect up to $1.2 billion in commercial milestones.6 The agreement covers the ongoing Phase II RENAL study in ANCA-associated vasculitis with rapidly progressive glomerulonephritis, as well as development in focal segmental glomerulosclerosis and primary sclerosing cholangitis.69

Alentis reported that an interim analysis of 26 RENAL patients found improvements in kidney function and proteinuria after 24 weeks.10 The company also reported improved liver function after six weeks in a Phase Ib study of lixudebart in advanced liver fibrosis.10

Shionogi plans $2 billion purchase of IntraBio and its rare-disease drug

Shionogi announced on October 5 that it would acquire IntraBio for $2 billion, gaining global rights to Aqneursa if the deal closes.78 Aqneursa is approved in the United States and Europe for neurological symptoms of Niemann-Pick disease type C. The FDA expanded its US use to ataxia-telangiectasia, and European regulators are reviewing the drug for that condition.78

Shionogi said Aqneursa generated $67.8 million in fiscal 2025 revenue and that it expects the acquisition to close by year-end, subject to regulatory review.8 The purchase would add to Shionogi’s rare-disease portfolio after its acquisition of global rights to the amyotrophic lateral sclerosis drug Radicava earlier in 2026.78